Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

NCT00449644 is registered in ClinicalTrials.gov with Janssen Infectious Diseases BVBA as lead sponsor.

NCT NCT00449644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00449644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).
Lead sponsor
Janssen Infectious Diseases BVBA
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
October 31, 2012
Enrollment
208 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis